Symbol
| TGM2
| contributors: mct/pgu - updated : 16-05-2018
|
HGNC name
| transglutaminase 2 (C polypeptide, protein-glutamine-gamma-glutamyltransferase)
|
HGNC id
| 11778
|
Other morbid association(s)
|
Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
---|
tumoral
|  
|  
| --over
|  
|
overexpressed in ovarian cancer and promoting intraperitoneal metastasis | constitutional
|  
|  
| --over
|  
|
overexpressed in cystic fibrosis and affecting NDPK function  | constitutional
|  
|  
| --over
|  
|
in neurons exposed to oxygen and glucose deprivation (OGD), and increased TGM2 expression protects neurons against OGD-induced cell death independent of its transamidating activity  | |
Susceptibility
|
to schizophrenia  |
Variant & Polymorphism
|
| |
Candidate gene
Marker
| can serve as a biomarker for all grades of cervical dysplasia  | |
may be used in diagnosis of pediatric mastocytosis, particularly systemic mastocytosis (SM)  | Therapy target
|
System | Type | Disorder | Pubmed |
cancer | | |  |
inhibition of TGM2 may offer a novel strategy for anticancer therapy | cancer | metastases | |  |
inhibiting TGM2 may offer a novel therapeutic approach for managing and treatment of metastatic cancer | cardiovascular | aquired | |  |
is a potential therapeutic target for blocking neointima in blood vessels |
| | |
| glucose homeostasis in mice is Tgm2 independent  |